NovaBay Pharmaceuticals

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Retrieved on: 
Wednesday, March 13, 2024
Clobetasol, NBY, Physician, Inflammation, Patient, Food and Drug Administration, NovaBay Pharmaceuticals, Pain, FDA, Ophthalmology, Food, Pharmaceutical industry

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.

Key Points: 
  • EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
  • Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
  • Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023.
  • This co-promotion agreement reflects our shared commitment to bring scientifically developed, cutting-edge and high-quality ophthalmic products to physicians and the patients they treat.”

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Optical, Health, Research and development, PIN, Growth, NBY, G&A, Co-promotion, Amazon (company), OTC, Marketing, NovaBay Pharmaceuticals, Pharmaceutical industry

(NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
  • Net product revenue for the fourth quarter of 2023 included $2.8 million from the eyecare and wound care segment, and $0.9 million from the skincare segment.
  • Gross margin on net product revenue for the fourth quarter of 2023 was 49%, compared with 48% for the fourth quarter of 2022.
  • Research & development (R&D) expenses also decreased for the fourth quarter of 2023 to $4 thousand, versus $66 thousand for the prior-year period.

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024

Retrieved on: 
Monday, March 25, 2024
Cosmetics, Medical Supplies, Retail, Health, Pharmaceutical, Optical, Biotechnology, Webcast, PIN, NovaBay Pharmaceuticals, NBY

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.

Key Points: 
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
  • Participants may pre-register at any time, including up to and after the call start time.
  • Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
    833-816-1121 from within the U.S.
    412-317-1862 from outside the U.S.
  • The live webcast of the conference call also will be available on the Events section of the Company website.

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

Retrieved on: 
Tuesday, January 30, 2024
Growth, Regenerative medicine, FSS, Regulation, Patient, Disclosure, SDVOSB, OTC, Regulation Fair Disclosure, Defense, DAPA, NovaBay Pharmaceuticals, HCPCS

POMPANO BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, today highlights its 2023 accomplishments and provides a business update.

Key Points: 
  • BioStem Technologies CEO, Jason Matuszewski, said, “2023 was a year of tremendous growth, progress and achievement for BioStem.
  • This growth is primarily attributed to the successful launch of Amniowrap2™, our innovative placental-derived allograft product designed to address a broad spectrum of wound applications.
  • BioStem Technologies appointed a proven life science sales leader, Mr. Shawn McCarrey, as Chief Commercial Officer.
  • BioStem will host a conference call and webcast to discuss fourth quarter and full year 2023 financial results in March 2024.

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Women, Consumer, Health, Optical, Chek, NovaBay Pharmaceuticals, NBY, Amazon (company)

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.
  • A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022.
  • In addition, of the more than 13,000 customer reviews across all online channels, Avenova Spray averaged a 4.5-star overall rating.
  • “Generating sales through the subscriber base provides efficient and consistent revenue, allowing us to better manage our sales and marketing spend.

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

Retrieved on: 
Tuesday, January 9, 2024
Medical Supplies, Marketing, Communications, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Optical, NBY, European, General counsel, NovaBay Pharmaceuticals, Blepharitis, Eyelash, Irritation, Sale, Hypochlorous acid, Inflammation, Red, Eyelid, Cosmetics

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union.
  • This agreement brings together NovaBay’s deep knowledge of eye care reflected in its Avenova brand with Sonoma’s expertise in distributing hypochlorous acid products overseas.
  • “Sonoma has built a strong and growing presence in the European Union through a network of distributors and direct sales.
  • “The EU market is comparable in size to the U.S., giving NovaBay the opportunity to double its sales of Avenova.

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

Retrieved on: 
Wednesday, December 6, 2023
Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Chek, NBY, NovaBay Pharmaceuticals, NYSE, General counsel, Conjunctiva, Report, Partnership, Education

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes.
  • A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here .
  • In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
  • Woo University is a non-profit organization committed to providing high-quality continuing education to eyecare professionals around the world.

NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Cosmetics, Medical Supplies, Retail, Health, Pharmaceutical, Optical, Biotechnology, NBY, Ophthalmology, Shareholder, NYSE, PIN, Patient, NovaBay Pharmaceuticals, Marketing, Research and development, G&A, Series, Total, Operating cost, R, Optometry, Pharmaceutical industry, Video game, Security (finance), Cryptocurrency, Clothing

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • Gross margin on net product revenue for the third quarter of 2023 was 56%, compared with 62% for the third quarter of 2022, with the decrease primarily due to product and channel mix.
  • Total operating expenses for the third quarter of 2023 were $3.0 million, compared with $2.8 million for the third quarter of 2022.
  • Net loss attributable to common stockholders for the third quarter of 2023 was $1.8 million, or $0.37 per share.

NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

Retrieved on: 
Thursday, November 2, 2023
Research, General Health, Online Retail, Family, Optical, Consumer, Retail, Clinical Trials, Science, Biotechnology, Women, Health, Other Science, NovaBay Pharmaceuticals, NYSE, NBY, Webcast, PIN, Pharmaceutical industry

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Key Points: 
  • NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
  • Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
  • Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
    833-816-1121 from within the U.S.
    412-317-1862 from outside the U.S.
  • The live webcast of the conference call also will be available on the Events section of the Company website.

Key Players in the Global Wound Cleanser Market Showcase Innovative Solutions - Report Profiles Leading Companies and Their Contributions to Wound Care - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Diabetes, Chemicals, Plastics, Health, Manufacturing, Law Enforcement, Emergency Services, Other Health, Surgery, Medical Devices, Infectious Diseases, General Health, Hospitals, Other Manufacturing, Nursing, Medical Supplies, Argentum, Incidence, Partnership, NovaBay Pharmaceuticals, Medline Industries, Defense, Skin, FDA, LP, Göran Gentele, Growth, Inc., Defense Logistics Agency, Convatec, Smith & Nephew, Patient, Cosmetics, Limited

In November 2022, InfuSystem Holdings, Inc. and Sanara MedTech Inc. formed a partnership for SI Wound Care, LLC, offering innovative wound care solutions.

Key Points: 
  • In November 2022, InfuSystem Holdings, Inc. and Sanara MedTech Inc. formed a partnership for SI Wound Care, LLC, offering innovative wound care solutions.
  • What are the major market drivers, challenges, and opportunities in the global wound cleanser market?
  • What is the growth potential of the global wound cleanser market in North America, Europe, Asia-Pacific, and Latin America and Rest-of-the-World?
  • What is the supply chain scenario in the global wound cleanser market?